"Tumor Microenvironment" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The milieu surrounding neoplasms consisting of cells, vessels, soluble factors, and molecules, that can influence and be influenced by, the neoplasm's growth.
| Descriptor ID |
D059016
|
| MeSH Number(s) |
G04.366.500
|
| Concept/Terms |
Tumor Microenvironment- Tumor Microenvironment
- Microenvironment, Tumor
- Microenvironments, Tumor
- Tumor Microenvironments
Cancer Microenvironment- Cancer Microenvironment
- Cancer Microenvironments
- Microenvironment, Cancer
- Microenvironments, Cancer
|
Below are MeSH descriptors whose meaning is more general than "Tumor Microenvironment".
Below are MeSH descriptors whose meaning is more specific than "Tumor Microenvironment".
This graph shows the total number of publications written about "Tumor Microenvironment" by people in this website by year, and whether "Tumor Microenvironment" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2010 | 2 | 1 | 3 |
| 2011 | 3 | 4 | 7 |
| 2012 | 5 | 8 | 13 |
| 2013 | 8 | 4 | 12 |
| 2014 | 4 | 7 | 11 |
| 2015 | 14 | 7 | 21 |
| 2016 | 7 | 13 | 20 |
| 2017 | 11 | 10 | 21 |
| 2018 | 11 | 16 | 27 |
| 2019 | 17 | 17 | 34 |
| 2020 | 3 | 18 | 21 |
| 2021 | 12 | 26 | 38 |
| 2022 | 3 | 27 | 30 |
| 2023 | 1 | 27 | 28 |
| 2024 | 16 | 23 | 39 |
| 2025 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Tumor Microenvironment" by people in Profiles.
-
Neutrophil extracellular traps promote pre-metastatic niche formation in the omentum by expanding innate-like B cells that express IL-10. Cancer Cell. 2025 Jan 13; 43(1):69-85.e11.
-
Engineered GM-CSF polarizes protumorigenic tumor-associated macrophages to an antitumorigenic phenotype and potently synergizes with IL-12 immunotherapy. J Immunother Cancer. 2024 Dec 22; 12(12).
-
Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours. Nature. 2025 Jan; 637(8048):1218-1227.
-
Harnessing Antitumor Immunity in Ovarian Cancer. Cold Spring Harb Perspect Med. 2024 Dec 02; 14(12).
-
High tumor glucocorticoid receptor expression in early-stage, triple-negative breast cancer is associated with increased T-regulatory cell infiltration. Breast Cancer Res Treat. 2025 Feb; 209(3):563-572.
-
Cancer cells restrict immunogenicity of retrotransposon expression via distinct mechanisms. Immunity. 2024 12 10; 57(12):2879-2894.e11.
-
Bifunctional Metal-Organic Framework Synergistically Enhances Radiotherapy and Activates STING for Potent Cancer Radio-Immunotherapy. Angew Chem Int Ed Engl. 2025 Jan 27; 64(5):e202417027.
-
Multi-platform biomarkers of response to an immune checkpoint inhibitor in the neoadjuvant I-SPY 2 trial for early-stage breast cancer. Cell Rep Med. 2024 Nov 19; 5(11):101799.
-
Dendritic cell-intrinsic PTPN22 negatively regulates antitumor immunity and impacts anti-PD-L1 efficacy. J Immunother Cancer. 2024 Oct 26; 12(10).
-
Regulatory roles of NAMPT and NAD+ metabolism in uterine leiomyoma progression: Implications for ECM accumulation, stemness, and microenvironment. Redox Biol. 2024 Dec; 78:103411.